SAGE Therapeutics (SAGE) Stock Rating Reaffirmed by JPMorgan Chase & Co.

SAGE Therapeutics (NASDAQ:SAGE)‘s stock had its “buy” rating reaffirmed by investment analysts at JPMorgan Chase & Co. in a report issued on Wednesday.

SAGE has been the topic of a number of other research reports. Royal Bank of Canada lowered their target price on shares of SAGE Therapeutics from $145.00 to $137.00 and set an “outperform” rating on the stock in a research note on Monday, November 27th. Chardan Capital reissued a “hold” rating on shares of SAGE Therapeutics in a research note on Wednesday, September 13th. SunTrust Banks set a $82.00 target price on shares of SAGE Therapeutics and gave the company a “buy” rating in a research note on Thursday, October 19th. BMO Capital Markets reaffirmed a “buy” rating and set a $80.00 price objective on shares of SAGE Therapeutics in a research note on Friday, October 27th. Finally, Leerink Swann upped their price objective on shares of SAGE Therapeutics from $85.00 to $123.00 and gave the stock a “positive” rating in a research note on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $171.21.

Shares of SAGE Therapeutics (SAGE) opened at $171.01 on Wednesday. The firm has a market cap of $7,020.00, a PE ratio of -24.89 and a beta of 3.05. SAGE Therapeutics has a 52 week low of $44.55 and a 52 week high of $173.74.

SAGE Therapeutics (NASDAQ:SAGE) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.98) by $0.01. The company’s revenue for the quarter was up .0% on a year-over-year basis. equities analysts anticipate that SAGE Therapeutics will post -7.42 earnings per share for the current fiscal year.

In other news, insider Albert Robichaud sold 60,000 shares of the company’s stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $159.43, for a total transaction of $9,565,800.00. Following the transaction, the insider now directly owns 152,759 shares in the company, valued at $24,354,367.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jeffrey M. Jonas sold 210,247 shares of the company’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $157.45, for a total transaction of $33,103,390.15. Following the transaction, the chief executive officer now owns 211,473 shares in the company, valued at $33,296,423.85. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of SAGE Therapeutics by 11.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 138 shares in the last quarter. Keybank National Association OH lifted its position in shares of SAGE Therapeutics by 10.6% during the second quarter. Keybank National Association OH now owns 3,798 shares of the biopharmaceutical company’s stock worth $302,000 after purchasing an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of SAGE Therapeutics by 19.6% during the second quarter. Ameritas Investment Partners Inc. now owns 3,034 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 497 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of SAGE Therapeutics by 0.9% during the second quarter. Ameriprise Financial Inc. now owns 59,336 shares of the biopharmaceutical company’s stock worth $4,723,000 after purchasing an additional 552 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System lifted its position in shares of SAGE Therapeutics by 5.7% during the second quarter. State Board of Administration of Florida Retirement System now owns 12,742 shares of the biopharmaceutical company’s stock worth $1,015,000 after purchasing an additional 686 shares in the last quarter. Institutional investors own 95.33% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “SAGE Therapeutics (SAGE) Stock Rating Reaffirmed by JPMorgan Chase & Co.” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://transcriptdaily.com/2018/01/10/sage-therapeutics-sage-stock-rating-reaffirmed-by-jpmorgan-chase-co.html.

SAGE Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply